Condition: Chronic Hepatitis B · Sponsor: Michael Hoelscher
This study is an open-label, ascending dose phase 1b/2a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.
This description comes directly from the study's public registry record.
Otto Geisenberger, Dr.rer.nat. · +49-89-4400598 · otto.geisenberger@med.uni-muenchen.de
Always discuss trial participation with your own doctor first.
| Investigational Site GUF | Frankfurt, Germany | Recruiting |
| Investigational Site UKE | Hamburg, Germany | Recruiting |
| Investigational Site MHH | Hanover, Germany | Not Yet Recruiting |
| Investigational Site Uni Leipzig | Leipzig, Germany | Recruiting |
| Investigational Site LMU | Munich, Germany | Recruiting |
| Investigational Site TUM | Munich, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06513286